drugset
drugset / Trial / NCT05317312

Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.

NCT05317312 ↗

Phase 2 Completed 111 enrolled Mylan Specialty, LP
RandomizedParallel-groupDouble-blindTreatment

Summary

MR-107A-02 is being studied to investigate its efficacy, safety and dose-response after dental surgery.

Timeline

Start
2022-03-31
Primary completion
2022-06-15
Completion
2022-06-20

Outcome

Met primary endpoint

registry MR-107A-02 5 mg Twice in a 24 Hour Period vs Placebo Twice in a 24 Hour Period; p <0.001; Mean Difference (Final Values) 34.7 NCT05317312 ↗

registry MR-107A-02 15 mg Twice in a 24 Hour Period vs Placebo Twice in a 24 Hour Period; p <0.001; Mean Difference (Final Values) 42.8 NCT05317312 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject MR-107A-02 Unknown 1.25 mg Oral
Subject MR-107A-02 Unknown 5 mg Oral
Subject MR-107A-02 Unknown 15 mg Oral

Indications

No indication recorded.